|
|
|
|
|
|
Sponsored by: |
Bristol-Myers Squibb |
Information provided by: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT00409838 |
The purpose of the study is to demonstrate the clinical efficacy of abatacept (fixed dose ~ 10mg/kg) compared with placebo on a background of methotrexate after six months of treatment in patients with active RA and an inadequate clinical response to methotrexate
Condition | Intervention | Phase |
Rheumatoid Arthritis |
Drug: Placebo Drug: abatacept versus placebo |
Phase III |
MedlinePlus related topics: | Rheumatoid Arthritis |
Drug Information available for: | Methotrexate Abatacept |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase III, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Abatacept Administered Intravenously in Korean Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate |
Enrollment: | 113 |
Study Start Date: | April 2007 |
Study Completion Date: | July 2008 |
Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
A1: Placebo Comparator |
Drug: Placebo
solution, intravenous, 0 mg, every 28 days, 6 months and 12 months open-label
|
A2: Placebo Comparator |
Drug: abatacept versus placebo
solution, intravenous, 10 mg, every 28 days, 6 months and 12 months open-label
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Korea, Republic of | |||||
Local Institution | |||||
Seoul, Korea, Republic of, 137040 | |||||
Local Institution | |||||
Seoul, Korea, Republic of, 110-744 | |||||
Local Institution | |||||
Seoul, Korea, Republic of, 138-736 | |||||
Local Institution | |||||
Daegu, Korea, Republic of, 705-718 | |||||
Local Institution | |||||
Anyang, Korea, Republic of, 431-070 | |||||
Local Institution | |||||
Daejeon, Korea, Republic of, 302-799 | |||||
Korea, Republic of, Sungdong-Gu | |||||
Local Institution | |||||
Seoul, Sungdong-Gu, Korea, Republic of, 133-792 |
Bristol-Myers Squibb |
Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
BMS Clinical Trials Disclosure 
  |
For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm 
  |
Responsible Party: | Bristol-Myers Squibb ( Study Director ) |
Study ID Numbers: | IM101-124 |
First Received: | December 8, 2006 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00409838 |
Health Authority: | Korea: Food and Drug Administration |
|
|
|
|
|